COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce meetings with Thai Cannabis Corp. and senior government officials and advisors regarding environmental and commercial benefits of medical cannabis.
Cannabis Science and our associates in Thailand are constructing a business relationship that will allow for the necessary clinical trials to take place in Thailand with approval of the Thai governmental. The intent is to formalize a mutually beneficial partnership in the medical cannabis tourism industry. Concurrently, Thailand will serve as a staging ground for Cannabis Science to test and develop our products as we move toward our ultimate goal of U.S. FDA approved cannabis extract based medicines. The Thai people will benefit from our collaborative efforts in that income and knowledge generated by medical cannabis tourism will offset medical costs for the Thai people. It should be noted that Thailand ?? with a population of approximately 68 million ?? has a first class medical system that draws patients from around the world, so everyone can benefit from its integration of medical cannabis into modern health care.
Robert Melamede, Ph.D., Cannabis Science’s CEO stated, “It was amazing to meet with enlightened government officials who recognize the health, environmental, and commercial benefits of hemp and medical cannabis. Thailand now leads the world in having created intelligent policies so that the Thai people, and others from around the world, will benefit from the health promoting properties of the cannabis plant that have been so foolishly suppressed by American led policies of fear and ignorance.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.